ABHD17B

Across TCGA pan-cancer cohorts, ABHD17B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ABHD17B data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ABHD17B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ABHD17B expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where ABHD17B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	III,IV	0.916	0.486	.011	10	view →
PDAC	DFS	Quartile	II,III,IV	0.651	0.909	.015	10	view →
LUAD	DFS	Median	All	0.898	1.000	.021	8	view →
CCRCC	OS	Tertile	All	0.934	0.670	.026	5	view →
GBM	DFS	Quartile	All	0.789	0.544	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ABHD17B–LSCC (DFS)

Open the LSCC breakdown →